Biotransformation of mestranol to ethinyl estradiol in vitro: The role of cytochrome P-450 2C9 metabolic inhibitors

Journal of Clinical Pharmacology

Volumn 37, Issue 3, 1997, Pages 193-200

  Schmider, Jürgen ^a   Greenblatt, David J ^a   Von Moltke, Lisa L ^a   Karsov, Dmitri ^a   Vena, Richard ^a   Friedman, Hylar L ^b   Shader, Richard I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450 INHIBITOR; ESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MESTRANOL; MESTRANOL PLUS NORETHISTERONE; MICONAZOLE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; QUINIDINE; SULFAPHENAZOLE; TROLEANDOMYCIN;

ARTICLE; DEMETHYLATION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG TRANSFORMATION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; ORAL CONTRACEPTION;

EID: 0030978662     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04781.x     Document Type: Article

References (44)

1. Back DJ, Bates M, Breckenridge AM, Ellis A, Hall JM, Maciver M, et al: The in vitro metabolism of ethinyloestradiol, mestranol and levonorgestrel by human jejunal mucosa. Br J Clin Pharmacol 1981;11:275-278.
2. Kappus H, Bolt HM, Remmer H: Demethylation of mestranol to ethinyloestradiol in vitro and in vivo. Acta Endocrinol 1972;71:374-384.
3. Kappus H, Bolt HM, Remmer H: Affinity of ethinyl-estradiol and mestranol for the uterine estrogen receptor and for the microsomal mixed function oxidase of the liver. J Steroid Biochem 1973;4:121-128.
4. Warren RJ, Fotherby K: Plasma levels of ethinyloestradiol after administration of ethinyloestradiol or mestranol to human subjects. J Endocrinol 1973;59:369-370.
5. Longcope C, Williams KIH: Ethinylestradiol and mestranol: their pharmacodynamics and effects on natural estrogens. In, Garattini S, HW Berendes (eds.): Pharmacology of Steroid Contraceptive Drugs. New York: Raven Press, 1977;89-98.
6. Goldzieher JW, Dozier TS, de la Pena A: Plasma levels and pharmacokinetics of ethinyl estrogens in various populations: II. mestranol. Contraception 1980;21:17-27.
7. Goldzieher JW: Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications. Am J Obstet Gynecol 1990;163:318-322.
8. Bolt HM, Bolt WH: Pharmacokinetics of mestranol in man in relation to its oestrogenic activity. Eur J Clin Pharmacol 1974;7:295-305.
9. Bird CE, Clark AE: Metabolic clearance rates and metabolism of mestranol and ethinylestradiol in normal young women. J Clin Endocrinol Metabol 1973;36:296-302.
10. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI: Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993;47:268-276.
11. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI: Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-1283.
12. Norby J, Rubenstein S, Tuerke T, Farmer S, Forood R, Bennington J: SigmaPlot. Jandel Corporation, 1991.
13. Chang TK, Gonzalez FJ, Waxman DJ: Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 1994;311:437-442.
14. Newton DJ, Wang RW, Lu AY: Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995;23:154-158.
15. O'Reilly RA, Goulart DA, Kunze KL, Neal J, Gibaldi M, Eddy AC, Trager WF: Mechanisms of the stereoselective interaction between miconazole and racemic: warfarin in human subjects. Clin Pharmacol Ther 1992;51:656-667.
16. Colquhoun MC, Daly M, Stewart P, Beeley L: Interaction between warfarin and miconazole oral gel. Lancet 1987;1:695-696.
17. Long E: Warfarin-miconazole interaction. Arch Intern Med 1983;143:2214-2215.
18. Bonay M, Jonville-Bera AP, Diot P, Lemarie E, Lavandier M, Autret E: Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf 1993;9:309-311.
19. Crane JK, Shih HT: Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 1993;95:445-446.
20. Kramer MR, Marshall SE, Denning DW, Keogh AM, Tucker RM, Galgiani JN, et al: Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990;113:327-329.
21. Olkkola KT, Backman JT, Neuvonen PJ: Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-485.
22. Shaw MA, Gumbleton M, Nicholls PJ: Interaction of cyclosporin and itraconazole. Lancet 1987;2:637.
23. Varhe A, Olkkola KT, Neuvonen PJ: Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-607.
24. Cadle RM, Zenon G, Rodriguez-Barradas MC, Hamill RJ: Fluconazole-induced symptomatic phenytoin toxicity. Ann Pharmacother 1994;28:191-195.
25. Mitchell AS, Holland JT: Fluconazole and phenytoin: a predictable interaction. BMJ 1989;298:1315.
26. Nation RL, Evans AM, Milne RW: Pharmacokinetic drug interactions with phenytoin (part I). Clin Pharmacokinet 1990;18:37-60.
27. Baciewicz AM, Menke JJ, Bokar JA, Baud EB: Fluconazole-warfarin interaction. Ann Pharmacother 1994;28:1111.
28. Gericke KR: Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993;13:508-509.
29. Wells PS, Holbrook AM, Crowther NR, Hirsh J: Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676-683.
30. Kerr HD: Case report: potentiation of warfarin by fluconazole. Am J Med Sci 1993;305:164-165.
31. Seaton TL, Celum CL, Black DJ: Possible potentiation of warfarin by fluconazole. Ann Pharmacother 1990;24:1177-1178.
32. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI: N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms, and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995;275:592-597.
33. Schmider J, Greenblatt DJ, Harmatz JS, Shader RI: Enzyme kinetic modeling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation. Br J Clin Pharmacol 1996;41:593-604.
34. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI: Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antideprassants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.
35. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI: In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 1994;34:1222-1227.
36. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ: Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995; 25:261-270.
37. Magnasco AJ, Magnasco LD: Interaction of ketoconazole and ethanol. Clin Pharm 1986;5:522-523.
38. Murphy E, Hannon D, Callaghan B: Ketoconazole-theophylline interaction. Ir Med J 1987;80:123-124.
39. Krishnaiah YS, Satyanarayana S, Visweswaram D: Interaction between tolbutamide and ketoconazole in healthy subjects. Br J Clin Pharmacol 1994;37:205-207.
40. Guengerich FP: Oxidation of 17 α-ethinylestradiol by human liver cytochrome P-450. Mol Pharmarol 1988;33:500-508.
41. Daneshmend TK, Warnock DW: Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988;14:13-34.
42. Heykants J, Van Peer A, Lavrijsen K, Meuldermans W, Woestenborghs R, Cauwenbergh G: Pharmacokinetics of oral antifungals and their clinical implications. Br J Clin Pract 1990;44(suppl 71):50-56.
43. Bennet JE: Antifungal agents. In, Hardman JG, A Goodman, LE Limbird (eds.): Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996;1175-1190.
44. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI: Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996;16:104-113.